517 related articles for article (PubMed ID: 28210673)
1. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.
Kidd M; Modlin IM; Bodei L; Drozdov I
Cell Mol Gastroenterol Hepatol; 2015 Mar; 1(2):131-153. PubMed ID: 28210673
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M; Stalla GK
Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
[TBL] [Abstract][Full Text] [Related]
3. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
4. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
6. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
7. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
[TBL] [Abstract][Full Text] [Related]
8. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns.
Chatterton DE; Nguyen DN; Bering SB; Sangild PT
Int J Biochem Cell Biol; 2013 Aug; 45(8):1730-47. PubMed ID: 23660296
[TBL] [Abstract][Full Text] [Related]
10. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.
Wang Y; Wang W; Jin K; Fang C; Lin Y; Xue L; Feng S; Zhou Z; Shao C; Chen M; Yu X; Chen J
Oncol Lett; 2017 Mar; 13(3):1165-1174. PubMed ID: 28454229
[TBL] [Abstract][Full Text] [Related]
12. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.
Svejda B; Kidd M; Timberlake A; Harry K; Kazberouk A; Schimmack S; Lawrence B; Pfragner R; Modlin IM
Cancer Sci; 2013 Jul; 104(7):844-55. PubMed ID: 23578138
[TBL] [Abstract][Full Text] [Related]
13. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
Arsenault RJ; Kogut MH; He H
Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
15. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
Er LM; Wu ML; Gao Y; Wang SJ; Li Y
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic Neuroendocrine Tumors-Current Status and Advances in Diagnostic Imaging.
Vogele D; Schmidt SA; Gnutzmann D; Thaiss WM; Ettrich TJ; Kornmann M; Beer M; Juchems MS
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685279
[TBL] [Abstract][Full Text] [Related]
17. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
Fottner C; Ferrata M; Weber MM
Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
Anlauf M
Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
[TBL] [Abstract][Full Text] [Related]
19. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Bech PR; Martin NM; Ramachandran R; Bloom SR
Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
